drugset / Trial / NCT04355247

Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm

NCT04355247

Phase 2 Unknown 20 enrolled Auxilio Mutuo Cancer Center
NaSingle-groupOpen-labelPrevention

Summary

This is a Phase II pilot exploratory study designed to investigate if prophylactic treatment with short term steroids administered to high risk Covid-19 patient might prevent cytokine storm and progression to respiratory failure. High risk is defined based on serologic markers of inflammation that include abnormalities of Interleukin 6 (IL-6), Ferritin , D-dimer, Lactate Dehydrogenase (LDH), as well as lymphopenia and impaired O2 saturation prior to or on the 7th day of first symptom of Covid-19.

Timeline

Start
2020-04-14
Primary completion
2020-07-31
Completion
2021-04-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylprednisolone Other / unclassified 80 mg Intravenous

Indications